Previous studies reveal that SRC kinase and FGFRs are common targets for ponatinib, dasatinib and bosutinib but they are not inhibited by imatinib and nilotinib (Moslehi and Deininger, 2015; Rossari et al., 2018; Zeng and Schmaier, 2020; Lee et al., 2021) which is consistent with our observation that ponatinib, dasatinib, bosutinib but not imatinib and nilotinib induce dorsal aorta stenosis in zebrafish (Figure 1B), so we hypothesized that inhibition of SRC or FGFRs is involved in the vasculopathies of CML TKIs. The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.